Genzyme: The Synvisc-One Investment Decision
Executives at biotechnology firm Genzyme are debating funding a clinical trial for a new version of a medical device called Synvisc. The trial is expensive and the odds of success are not high, but the upside is substantial. The case presents a common business question: invest or not? The case forces students to think about customer insights, wrestle with a number of complex issues, and evaluate the financials of the decision.
Timothy Calkins, Ann Deming
Calkins, Timothy, and Ann Deming. Genzyme: The Synvisc-One Investment Decision. Case 5-110-001 (KEL439).